Tilray Brands, Inc. (TLRY)
Tilray Shows Some Nice Improvement In Q4
Canadian cannabis and beverage firm Tilray beat top and bottom street estimates for its fiscal Q4 period. The company has made strong progress on reducing its large debt pile. While progress is being made, shareholders are facing significant dilution over time.
Tilray Brands, Inc. (TLRY) Q4 2024 Earnings Call Transcript
Tilray Brands, Inc. (NASDAQ:TLRY ) Q4 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Robert Moskow - TD Cowen Andrew Carter - Stifel Aaron Grey - Alliance Global Partners Owen Bennett - Jefferies Frederico Gomes - ATB Capital Markets Conference Call Participants Berrin Noorata - Chief Corporate Affairs and Communications Officer Irwin Simon - Chairman and CEO Carl Merton - CFO Denise Faltischek - Chief Strategy Officer and Head of International Operator Hello, and thank you for joining today's conference call to discuss Tilray Brands' Financial Results for the Fourth Quarter and Fiscal Year 2024 ended May 31, 2024. [Operator Instructions] I'll now turn the call over to Ms.
Tilray Brands (TLRY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Tilray Brands (TLRY) give insight into how the company performed in the quarter ended May 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Tops Revenue Estimates
Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.
TLRY Stock: Tilray's Aphria RX Receives Cannabis Trading License in Germany
Tilray (NASDAQ: TLRY ) stock is on the move Monday as investors in the cannabis company react to it securing a trading license in Germany for its Aphria RX subsidiary. With this trading license, Aphria RX is now able to sell and distribute medical cannabis products to a wide range of locations.
Tilray Brands (TLRY) stock price has bottomed: July 29 will be key
Tilray Brands (NASDAQ: TLRY) stock price will be in the spotlight this week as it publishes its second-quarter financial results. These numbers will come at a time when it is hovering near its year-to-date low of $1.60.
Tilray Brands (TLRY) Lined Up for Q4 Earnings: What Awaits?
Tilray's (TLRY) product innovation, spanning medical cannabis formats, THC-infused beverages and pharmaceutical-grade medicines, enhances its ability to capture new market segments globally.
Tilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key Insights
Tilray Brands, Inc. (TLRY) closed at $1.89 in the latest trading session, marking a -1.56% move from the prior day.
Tilray Stock Pops as Germany Grants It a Cultivation Green Light
Tilray Brands (NASDAQ: TLRY ) stock jumped almost 3% early on July 22 after it got good news from Germany. The marijuana and beer company received a cultivation license from German authorities.
Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY?
Tilray Brands Inc (NASDAQ: TLRY) has made a significant stride in its European operations by securing a new cannabis cultivation license in Germany. This development, under the country's new Cannabis Act (MedCanG), is set to substantially boost the production capacity of Tilray's Aphria RX GmbH facility in Berlin.
Is Tilray Brands Stock a Buy?
Acquisitions have been a big part of Tilray's strategy. The company's business is much more diversified than it used to be.
Tilray Brands, Inc. (TLRY) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Tilray Brands, Inc. (TLRY) closed at $1.93, marking a +1.05% move from the previous day.
